MA37953A1 - Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase - Google Patents
Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductaseInfo
- Publication number
- MA37953A1 MA37953A1 MA37953A MA37953A MA37953A1 MA 37953 A1 MA37953 A1 MA 37953A1 MA 37953 A MA37953 A MA 37953A MA 37953 A MA37953 A MA 37953A MA 37953 A1 MA37953 A1 MA 37953A1
- Authority
- MA
- Morocco
- Prior art keywords
- hmg
- irbesartan
- coa reductase
- inhibitor
- capsule formulation
- Prior art date
Links
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title abstract 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title abstract 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title abstract 3
- 239000007963 capsule composition Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title abstract 3
- 229960002198 irbesartan Drugs 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120096036A KR20140030505A (ko) | 2012-08-31 | 2012-08-31 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| PCT/KR2013/007841 WO2014035190A1 (en) | 2012-08-31 | 2013-08-30 | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37953A1 true MA37953A1 (fr) | 2017-01-31 |
Family
ID=50183919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37953A MA37953A1 (fr) | 2012-08-31 | 2015-03-27 | Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20150231085A1 (enExample) |
| EP (1) | EP2890371A4 (enExample) |
| JP (1) | JP2015526509A (enExample) |
| KR (1) | KR20140030505A (enExample) |
| CN (1) | CN104602678A (enExample) |
| AR (1) | AR092385A1 (enExample) |
| AU (1) | AU2013309688A1 (enExample) |
| BR (1) | BR112015004091A2 (enExample) |
| CA (1) | CA2882738A1 (enExample) |
| CL (1) | CL2015000363A1 (enExample) |
| CO (1) | CO7350622A2 (enExample) |
| CR (1) | CR20150124A (enExample) |
| DO (1) | DOP2015000042A (enExample) |
| EA (1) | EA201590474A1 (enExample) |
| EC (1) | ECSP15010617A (enExample) |
| IL (1) | IL237425A0 (enExample) |
| IN (1) | IN2015DN01738A (enExample) |
| MA (1) | MA37953A1 (enExample) |
| MX (1) | MX2015002591A (enExample) |
| NI (1) | NI201500028A (enExample) |
| PE (1) | PE20150402A1 (enExample) |
| PH (1) | PH12015500395A1 (enExample) |
| RU (1) | RU2015111523A (enExample) |
| SG (1) | SG11201500580QA (enExample) |
| TW (1) | TW201414511A (enExample) |
| UY (1) | UY35000A (enExample) |
| WO (1) | WO2014035190A1 (enExample) |
| ZA (1) | ZA201502157B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| BR112019028235B1 (pt) * | 2017-07-25 | 2024-04-30 | Plexxikon, Inc. | Composições e seus métodos de preparação |
| CN110237070A (zh) * | 2019-05-10 | 2019-09-17 | 辽宁大学 | 厄贝沙坦在制备降血脂药物中的应用 |
| EP4247354A4 (en) * | 2020-11-18 | 2025-02-19 | Fb-Hrs, Llc | COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES |
| CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| WO2005118166A2 (en) * | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
| WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
| US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
| UA99758C2 (ru) * | 2008-03-28 | 2012-09-25 | Феррер Интернасиональ С.А. | Капсула для профилактики сердечно-сосудистых заболеваний |
| KR101230731B1 (ko) * | 2008-04-29 | 2013-02-07 | 한올바이오파마주식회사 | 약제학적 제제 |
| AU2010242938A1 (en) * | 2009-04-30 | 2011-11-17 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| MX2013000824A (es) * | 2010-07-21 | 2013-10-28 | Nucitec Sa De Cv | Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico. |
-
2012
- 2012-08-31 KR KR1020120096036A patent/KR20140030505A/ko not_active Ceased
-
2013
- 2013-08-29 AR ARP130103082A patent/AR092385A1/es unknown
- 2013-08-30 UY UY0001035000A patent/UY35000A/es not_active Application Discontinuation
- 2013-08-30 SG SG11201500580QA patent/SG11201500580QA/en unknown
- 2013-08-30 RU RU2015111523A patent/RU2015111523A/ru not_active Application Discontinuation
- 2013-08-30 EP EP13834178.9A patent/EP2890371A4/en not_active Withdrawn
- 2013-08-30 US US14/420,953 patent/US20150231085A1/en not_active Abandoned
- 2013-08-30 PE PE2015000255A patent/PE20150402A1/es not_active Application Discontinuation
- 2013-08-30 CN CN201380045368.3A patent/CN104602678A/zh active Pending
- 2013-08-30 MX MX2015002591A patent/MX2015002591A/es unknown
- 2013-08-30 IN IN1738DEN2015 patent/IN2015DN01738A/en unknown
- 2013-08-30 BR BR112015004091A patent/BR112015004091A2/pt not_active IP Right Cessation
- 2013-08-30 AU AU2013309688A patent/AU2013309688A1/en not_active Abandoned
- 2013-08-30 EA EA201590474A patent/EA201590474A1/ru unknown
- 2013-08-30 CA CA2882738A patent/CA2882738A1/en not_active Abandoned
- 2013-08-30 TW TW102131242A patent/TW201414511A/zh unknown
- 2013-08-30 WO PCT/KR2013/007841 patent/WO2014035190A1/en not_active Ceased
- 2013-08-30 JP JP2015529684A patent/JP2015526509A/ja active Pending
-
2015
- 2015-02-16 CL CL2015000363A patent/CL2015000363A1/es unknown
- 2015-02-24 PH PH12015500395A patent/PH12015500395A1/en unknown
- 2015-02-25 IL IL237425A patent/IL237425A0/en unknown
- 2015-02-26 DO DO2015000042A patent/DOP2015000042A/es unknown
- 2015-02-27 NI NI201500028A patent/NI201500028A/es unknown
- 2015-03-11 CR CR20150124A patent/CR20150124A/es unknown
- 2015-03-13 CO CO15058341A patent/CO7350622A2/es unknown
- 2015-03-20 EC ECIEPI201510617A patent/ECSP15010617A/es unknown
- 2015-03-27 MA MA37953A patent/MA37953A1/fr unknown
- 2015-03-30 ZA ZA2015/02157A patent/ZA201502157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015500395A1 (en) | 2015-04-27 |
| PE20150402A1 (es) | 2015-04-13 |
| CR20150124A (es) | 2015-04-24 |
| WO2014035190A1 (en) | 2014-03-06 |
| ZA201502157B (en) | 2016-10-26 |
| KR20140030505A (ko) | 2014-03-12 |
| DOP2015000042A (es) | 2015-04-30 |
| JP2015526509A (ja) | 2015-09-10 |
| UY35000A (es) | 2014-03-31 |
| SG11201500580QA (en) | 2015-02-27 |
| CN104602678A (zh) | 2015-05-06 |
| EP2890371A4 (en) | 2016-04-06 |
| BR112015004091A2 (pt) | 2017-07-04 |
| CL2015000363A1 (es) | 2015-06-05 |
| AR092385A1 (es) | 2015-04-22 |
| ECSP15010617A (es) | 2015-12-31 |
| MX2015002591A (es) | 2015-06-10 |
| AU2013309688A1 (en) | 2015-02-26 |
| TW201414511A (zh) | 2014-04-16 |
| EA201590474A1 (ru) | 2015-06-30 |
| RU2015111523A (ru) | 2016-10-20 |
| CO7350622A2 (es) | 2015-08-10 |
| EP2890371A1 (en) | 2015-07-08 |
| IN2015DN01738A (enExample) | 2015-05-29 |
| CA2882738A1 (en) | 2014-03-06 |
| NI201500028A (es) | 2017-01-04 |
| US20150231085A1 (en) | 2015-08-20 |
| IL237425A0 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30807B1 (fr) | Compositions pharmaceutiques. | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| MY178082A (en) | Solid pharmaceutical compositions and processes for their production | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| TW200733971A (en) | CGRP peptide antagonists and conjugates | |
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| PH12013501341A1 (en) | Morphinan compounds | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| MA37610B1 (fr) | Formulations de testostérone proliposomales | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| MX341482B (es) | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| AU2010212580A8 (en) | Stable pharmaceutical composition for atherosclerosis | |
| MA30779B1 (fr) | Comprimes pediatriques de capecitabine | |
| MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
| PH12015500395A1 (en) | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| UA107088C2 (xx) | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| MA39175A1 (fr) | Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives | |
| IN2015DN04172A (enExample) | ||
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| ATE482195T1 (de) | Benzoäfüisoindole als antagonisten des ep4- rezeptors | |
| TN2012000563A1 (fr) | Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent. |